Clinical Trials

18 enrolled

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07177079 2026-04-09

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

NCT06763341 2026-04-08

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Suspended

12 enrolled

Leukemia, Myeloid, Acute

NCT07133997 2026-04-07

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

26 enrolled

Burkitt Lymphoma

NCT07511062 2026-04-06

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

32 enrolled

Leukemia, Myeloid, Acute

NCT07374029 2026-04-03

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

Leukemia, Myeloid, Acute

NCT05618366 2026-04-02

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

Phase 1 Terminated

3 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03874052 2026-03-24

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

51 enrolled

Leukemia, Myeloid, Acute

NCT06152809 2026-03-18

CIML NK Cells With Venetoclax for AML

10 enrolled

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT04926285 2026-03-16

VEN-OM

6 enrolled

Recurrence, Hematologic Neoplasms

NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05834244 2026-03-11

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

32 enrolled

Leukemia, Myeloid, Acute

NCT03969446 2026-03-05

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

54 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05157971 2026-03-05

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

24 enrolled

Burkitt Lymphoma

NCT03844815 2026-03-04

Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

26 enrolled

Leukemia, Myeloid, Acute

NCT06177067 2026-03-04

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

24 enrolled

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT07044544 2026-03-04

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

20 enrolled

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07283094 2026-03-03

FHD-286

33 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07439211 2026-03-03

GAVEL

48 enrolled

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT06445907 2026-02-24

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

32 enrolled

Leukemia, Myeloid, Acute

NCT04964505 2026-02-23

Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

Phase 1 Terminated

16 enrolled

Leukemia, Myeloid, Acute

NCT03826992 2026-02-18

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

21 enrolled

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT06191978 2026-02-18

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

40 enrolled

Leukemia, Myeloid, Acute

NCT06863259 2026-02-18

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

28 enrolled

Burkitt Lymphoma, Recurrence

NCT05391750 2026-02-17

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

7 enrolled

Plasma cell

Multiple Myeloma

NCT05053659 2026-02-12

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

23 enrolled

Lymphoma, Non-Hodgkin

NCT04872790 2026-02-10

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

20 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT03485547 2026-02-02

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

5 enrolled

Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT05016947 2026-01-29

Venetoclax Plus Inotuzumab for B-ALL

23 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell

NCT05455294 2026-01-28

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

16 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT04898894 2026-01-26

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

37 enrolled

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT03709758 2026-01-16

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

50 enrolled

Leukemia, Myeloid, Acute

NCT06429449 2026-01-15

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

Leukemia, Leukemia, Monocytic, Acute, Leukemia, Myeloid

NCT05010772 2026-01-14

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

125 enrolled

Leukemia, Myeloid, Acute

NCT05317403 2026-01-12

Venetoclax to Augment Epigenetic Modification and Chemotherapy

40 enrolled

Leukemia, Myeloid, Acute

NCT05263284 2026-01-08

8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

NCT05342584 2026-01-08

Venetoclax AML

99 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05597306 2026-01-08

VenBom

18 enrolled

Leukemia, Myeloid, Acute

NCT04843904 2026-01-07

SAVE

40 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07320235 2026-01-06

IMAGINE

36 enrolled

Leukemia, Myeloid, Acute

NCT03613532 2025-12-24

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

102 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06042725 2025-12-24

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

100 enrolled

Plasma cell

Multiple Myeloma

NCT06448013 2025-12-15

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

22 enrolled

Leukemia, Myeloid, Acute

NCT05564650 2025-12-08

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

6 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT06454409 2025-11-19

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Suspended

20 enrolled

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05986240 2025-11-10

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

38 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03113643 2025-11-04

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

72 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04666649 2025-10-07

Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

27 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT04447716 2025-09-15

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

4 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT04512105 2025-09-11

Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

6 enrolled